Sensus Healthcare Expands International Business to Meet Rising Patient Demand for Non-Invasive Skin Cancer and Keloid Treatments

BOCA RATON, Fla.April 19, 2018 /PRNewswire/ — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announced today that the Company is expanding its global business with SRT to meet growing demand for non-invasive, highly effective skin cancer and keloid treatments. Rick Golin, Executive Vice President of Oncology and International Sales, will lead this expansion. As part of this, he will facilitate recently signed new distribution agreements in International markets.

Read the full press release here.

Share to:

Contact Us

Fill out the form below to find out more!